专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009048289A2 PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS C VIRUS INFECTION COMPRISING HMG-COA REDUCTASE INHIBITOR AND BILE ACID 审中-公开
标题翻译：用于治疗包含HMG-COA还原酶抑制剂和胆酸的丙型肝炎病毒感染的药物组合物
公开(公告)号：WO2009048289A2
公开(公告)日：2009-04-16
申请号：PCT/KR2008/005965
申请日：2008-10-10
申请人： HANALL PHARMACEUTICAL COMPANY. LTD , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , LEE, Jun Young
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , LEE, Jun Young
IPC分类号： A61K31/405 , A61K31/23 , A61K31/57 , C07K16/24 , A61P1/16 , A61P31/12
CPC分类号： A61K45/06 , A61K9/209 , A61K31/404 , A61K31/575 , A61K38/21 , A61K2300/00
摘要： Disclosed herein is a pharmaceutical composition for treating hepatitis C virus infection comprising an HMG-CoA reductase inhibitor and bile acid. More specifically, disclosed are a pharmaceutical composition for treating hepatitis C vims infection comprising fluvastatin or a pharmaceutically acceptable salt thereof along with ursodeoxycholic acid and a preparation method thereof.
摘要翻译：本文公开了用于治疗丙型肝炎病毒感染的药物组合物，其包含HMG-CoA还原酶抑制剂和胆汁酸。更具体地，公开了用于治疗丙型肝炎病毒感染的药物组合物及其制备方法，其包含氟伐他汀或其药学上可接受的盐以及熊去氧胆酸。

2. 发明申请

WO2009038396A3 N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 审中-公开
公开(公告)号：WO2009038396A3
公开(公告)日：2009-03-26
申请号：PCT/KR2008/005574
申请日：2008-09-19
申请人： HANALL PHARMACEUTICAL COMPANY. LTD , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong , KIM, Byoung Ha , KIM, Duck
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong , KIM, Byoung Ha , KIM, Duck
IPC分类号： C07C279/26
摘要： Disclosed herein are a novel dicarboxylic acid salt of N,N- dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N- dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as a preparation method thereof and a pharmaceutical composition comprising the same.

3. 发明申请

WO2009028891A2 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开
标题翻译： 1,3,5-三嗪-2,4,6-三胺化合物或药物可接受的盐及含有该化合物的药物组合物
公开(公告)号：WO2009028891A2
公开(公告)日：2009-03-05
申请号：PCT/KR2008/005062
申请日：2008-08-28
申请人： HANALL PHARMACEUTICAL COMPANY. LTD , KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , CHEON, Hyae Gyeong , KIM, Kwang-Rok , RHEE, Sang Dal , JUNG, Won Hoon , LEE, Jong-Cheol , KIM, Sung Wuk , JUN, Sung Soo
发明人： CHEON, Hyae Gyeong , KIM, Kwang-Rok , RHEE, Sang Dal , JUNG, Won Hoon , LEE, Jong-Cheol , KIM, Sung Wuk , JUN, Sung Soo
IPC分类号： C07D251/54
CPC分类号： C07D251/70 , A61K31/53 , C07D251/54 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12
摘要： Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.
摘要翻译：本文公开了1,3,5-三嗪-2,4,6-三胺化合物或其药学上可接受的盐，其制备方法和用于预防或治疗代谢综合症的组合物，糖尿病或缺失包含P53基因的癌症。

4. 发明申请

WO2009022821A2 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME 审中-公开
标题翻译：包含HMG-COA还原酶和阿司匹林抑制剂的组合制剂及其制造方法
公开(公告)号：WO2009022821A2
公开(公告)日：2009-02-19
申请号：PCT/KR2008/004623
申请日：2008-08-08
申请人： HANALL PHARMACEUTICAL COMPANY. LTD , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SUN, Sang Ouk
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SUN, Sang Ouk
IPC分类号： A61K31/35
CPC分类号： A61K31/35 , A61K31/616 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs.
摘要翻译：本发明涉及用于预防和治疗心血管疾病的时间治疗组合药物制剂，其基于以特定时间间隔施用多种药物的原理（时间疗法）。具体而言，组合药物制剂包含HMG-CoA还原酶抑制剂，例如辛伐他汀和阿司匹林。由于基于给予药物的原理以一定的时间间隔开发了所谓的时间疗法，所以与单独施用和同时施用单一制剂相比，其显示出预防或治疗心血管疾病的优异效果。此外，这是一种每日一次的剂型，可增加患者的用药依从性。特别是，即使组合药物制剂中阿司匹林的含量降低，阿司匹林在组合药物制剂中的血小板聚集抑制效果等于现有技术中使用的阿司匹林的量，而组合药物中的阿司匹林配方显示出抗高血压作用。此外，时效治疗组合药物制剂允许两种彼此相互作用的药物长时间储存，且组合药物制剂确保两种药物的人体安全性和功效。

5. 发明申请

WO2008093984A1 N, N- DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 审中-公开
标题翻译： N，N-二甲基咪唑二羧酸二乙酸酯，其制备方法和包含其的药物组合物
公开(公告)号：WO2008093984A1
公开(公告)日：2008-08-07
申请号：PCT/KR2008/000529
申请日：2008-01-29
申请人： HANALL PHARMACEUTICAL COMPANY. LTD , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong
IPC分类号： A61K31/155
CPC分类号： A61K31/155 , C07C279/26
摘要： The present invention relates to N,N -dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same.
摘要翻译：本发明涉及N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其制备方法和包含其的药物组合物，更具体地说，涉及作为结晶酸加成盐的N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其是由使N，N-二甲基亚氨基二亚甲基二酰胺与乙酸反应，作为治疗代谢综合征的糖尿病，糖尿病，肥胖症，高脂血症，脂肪肝，冠心病，骨质疏松症，多囊卵巢综合症，癌症，贫血基因P53等复杂发生; 治疗糖尿病并预防其并发症; 并且由于酸加成盐在溶解性，稳定性，非吸湿性，抗附着性等等的物理化学性质和低毒性方面都是优异的，因此治疗癌症并防止肌肉痛，肌肉细胞毒性和横纹肌溶解等。的制备方法和包含其的药物组合物。

6. 发明申请

WO2008054121A1 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THIAZIDES AND ANGIOTENSIN-II-RECEPTOR BLOCKERS 审中-公开
标题翻译：含有THIAZIDES和ANGIOTENSIN-II-受体阻断剂的受控释放的药物组合物
公开(公告)号：WO2008054121A1
公开(公告)日：2008-05-08
申请号：PCT/KR2007/005403
申请日：2007-10-30
申请人： HANALL PHARMACEUTICAL COMPANY. LTD , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Jin Wook , SON, Jae Woon
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Jin Wook , SON, Jae Woon
IPC分类号： A61K9/22 , A61K31/00 , A61K9/48
CPC分类号： A61K31/00 , A61K9/2086 , A61K9/209 , A61K31/549 , A61K45/06 , A61K2300/00
摘要： Disclosed herein is a pharmaceutical composition, containing a thiazide compound and an angiotensin-II-receptor blocker, and a technology for formulating the same. More particularly, disclosed is a pharmaceutical combination formulation of thiazide compound and angiotensin-II-receptor blocker, which maximizes the pharmacological and clinical antihypertensive effects and complication preventive effects of the drugs and reduces the side effects of the drugs, compared to when single-component formulations of the drugs are administered simultaneously.
摘要翻译：本文公开了含有噻嗪类化合物和血管紧张素-II-受体阻断剂的药物组合物及其制备方法。更具体地，公开了噻嗪类化合物和血管紧张素-II-受体阻断剂的药物组合制剂，其最大化药物的药理学和临床抗高血压作用和并发症预防作用，并降低药物的副作用，与单组分药物的配方同时给药。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式